Hepatitis Monthly

Published by: Kowsar

Green Tea in Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

Seyed Mohammad Tabatabaee 1 , Seyed Moayed Alavian 2 , Leila Ghalichi 3 , Seyed Mohammad Miryounesi 4 , Kazem Mousavizadeh 5 , 6 , Shima Jazayeri 1 and Mohammad Reza Vafa 1 , *
Authors Information
1 Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran; Middle East Liver Diseases (MELD) Center, Tehran, Iran
3 Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran
4 Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Cellular and Molecular Research Center (CMRC), Iran University of Medical Sciences, Tehran, Iran
6 Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
Article information
  • Hepatitis Monthly: December 2017, 17 (12); e14993
  • Published Online: September 10, 2017
  • Article Type: Research Article
  • Received: June 11, 2017
  • Accepted: August 28, 2017
  • DOI: 10.5812/hepatmon.14993

To Cite: Tabatabaee S M, Alavian S M, Ghalichi L, Miryounesi S M, Mousavizadeh K, et al. Green Tea in Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial, Hepat Mon. 2017 ;17(12):e14993. doi: 10.5812/hepatmon.14993.

Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Maher D, Harries AD, Zachariah R, Enarson D. A global framework for action to improve the primary care response to chronic non-communicable diseases: a solution to a neglected problem. BMC Public Health. 2009;9:355. doi: 10.1186/1471-2458-9-355. [PubMed: 19772598].
  • 2. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219-29. doi: 10.1016/S0140-6736(12)61031-9. [PubMed: 22818936].
  • 3. Pournik O, Dorri S, Zabolinezhad H, Alavian SM, Eslami S. A diagnostic model for cirrhosis in patients with non-alcoholic fatty liver disease: an artificial neural network approach. Med J Islam Repub Iran. 2014;28:116. [PubMed: 25678995].
  • 4. Malekzadeh R, Mohamadnejad M, Merat S, Pourshams A, Etemadi A. Obesity pandemic: an Iranian perspective. Arch Iranian Med. 2005;8(11):1-7.
  • 5. Sohrabpour A, Rezvan H, Amini-Kafiabad S, Dayhim M, Merat S, Pourshams A. Prevalence of Nonalcoholic Steatohepatitis in Iran: A Population based Study. Middle East J Dig Dis. 2010;2(1):14-9. [PubMed: 25197507].
  • 6. Pournik O, Alavian SM, Ghalichi L, Seifizarei B, Mehrnoush L, Aslani A, et al. Inter-observer and Intra-observer Agreement in Pathological Evaluation of Non-alcoholic Fatty Liver Disease Suspected Liver Biopsies. Hepat Mon. 2014;14(1). e15167. doi: 10.5812/hepatmon.15167. [PubMed: 24497882].
  • 7. Cho J, Koh Y, Han J, Kim D, Kim T, Kang H. Adiponectin mediates the additive effects of combining daily exercise with caloric restriction for treatment of non-alcoholic fatty liver. Int J Obes (Lond). 2016;40(11):1760-7. doi: 10.1038/ijo.2016.104. [PubMed: 27216820].
  • 8. Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepat Mon. 2016;16(1). e34897. doi: 10.5812/hepatmon.34897. [PubMed: 27110262].
  • 9. Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 2015;7(2):204-12. doi: 10.4254/wjh.v7.i2.204. [PubMed: 25729475].
  • 10. Dongiovanni P, Lanti C, Riso P, Valenti L. Nutritional therapy for nonalcoholic fatty liver disease. J Nutr Biochem. 2016;29:1-11. doi: 10.1016/j.jnutbio.2015.08.024. [PubMed: 26895659].
  • 11. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr. 2008;138(9):1677-83. [PubMed: 18716169].
  • 12. Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr. 2014;53(1):187-99. doi: 10.1007/s00394-013-0516-8. [PubMed: 23515587].
  • 13. Pezeshki A, Safi S, Feizi A, Askari G, Karami F. The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease. Int J Prev Med. 2016;7:28. doi: 10.4103/2008-7802.173051. [PubMed: 26955458].
  • 14. Sakata R, Nakamura T, Torimura T, Ueno T, Sata M. Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study. Int J Mol Med. 2013;32(5):989-94. doi: 10.3892/ijmm.2013.1503. [PubMed: 24065295].
  • 15. Nagao T, Hase T, Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring). 2007;15(6):1473-83. doi: 10.1038/oby.2007.176. [PubMed: 17557985].
  • 16. Fukuzawa Y, Kapoor MP, Yamasaki K, Okubo T, Hotta Y, Juneja LR. Effects of green tea catechins on nonalcoholic steatohepatitis (NASH) patients. J Funct Foods. 2014;9:48-59. doi: 10.1016/j.jff.2014.04.010.
  • 17. Mandel S, Amit T, Reznichenko L, Weinreb O, Youdim MB. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res. 2006;50(2):229-34. doi: 10.1002/mnfr.200500156. [PubMed: 16470637].
  • 18. Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ. 1995;310(6981):693-6. doi: 10.1136/bmj.310.6981.693. [PubMed: 7711535].
  • 19. Skrzydlewska E, Ostrowska J, Farbiszewski R, Michalak K. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. Phytomedicine. 2002;9(3):232-8. doi: 10.1078/0944-7113-00119. [PubMed: 12046864].
  • 20. Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr. 2010;29(1):31-40. doi: 10.1080/07315724.2010.10719814. [PubMed: 20595643].
  • 21. Coimbra S, Castro E, Rocha-Pereira P, Rebelo I, Rocha S, Santos-Silva A. The effect of green tea in oxidative stress. Clin Nutr. 2006;25(5):790-6. doi: 10.1016/j.clnu.2006.01.022. [PubMed: 16698148].
  • 22. Fargion S, Dongiovanni P, Guzzo A, Colombo S, Valenti L, Fracanzani AL. Iron and insulin resistance. Aliment Pharmacol Ther. 2005;22 Suppl 2:61-3. doi: 10.1111/j.1365-2036.2005.02599.x. [PubMed: 16225476].
  • 23. Babu PV, Sabitha KE, Shyamaladevi CS. Therapeutic effect of green tea extract on oxidative stress in aorta and heart of streptozotocin diabetic rats. Chem Biol Interact. 2006;162(2):114-20. doi: 10.1016/j.cbi.2006.04.009. [PubMed: 16860299].
  • 24. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem. 2004;15(9):506-16. doi: 10.1016/j.jnutbio.2004.05.002. [PubMed: 15350981].
  • 25. Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett. 2007;245(1-2):232-41. doi: 10.1016/j.canlet.2006.01.027. [PubMed: 16519995].
  • 26. Ortiz-Lopez L, Marquez-Valadez B, Gomez-Sanchez A, Silva-Lucero MD, Torres-Perez M, Tellez-Ballesteros RI, et al. Green tea compound epigallo-catechin-3-gallate (EGCG) increases neuronal survival in adult hippocampal neurogenesis in vivo and in vitro. Neuroscience. 2016;322:208-20. doi: 10.1016/j.neuroscience.2016.02.040. [PubMed: 26917271].
  • 27. Zaveri NT. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci. 2006;78(18):2073-80. doi: 10.1016/j.lfs.2005.12.006. [PubMed: 16445946].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader